Sensei Biotherapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 6, 2024

FTH$12.92+1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

	For the Three Months Ended June 30,		For the Six Months Ended June 30,
	2024	2023	2024	2023
Operating expenses:
Research and development	$4,584	$4,784	$9,501	$9,988
General and administrative	3,203	5,393	7,016	11,197
Total operating expenses	7,787	10,177	16,517	21,185
Loss from operations	(7,787)	(10,177)	(16,517)	(21,185)
Other income (expense):
Interest income	669	952	1,437	1,921
Interest expense	(24)	(38)	(52)	(80)
Loss on asset disposal	—	(191)	—	(296)
Other income (expense), net	—	68	(2)	77
Net loss	(7,142)	(9,386)	(15,134)	(19,563)
Net loss per common share, basic and diluted	$(0.28)	$(0.31)	$(0.60)	$(0.64)
Weighted-average number of shares used in computing net loss per common share, basic and diluted	25,104,439	30,507,018	25,076,775	30,685,561
Comprehensive loss:
Net loss	$(7,142)	$(9,386)	$(15,134)	$(19,563)
Other comprehensive items:
Unrealized gain on marketable securities	44	274	116	455
Total other comprehensive income	44	274	116	455
Total comprehensive loss	$(7,098)	$(9,112)	$(15,018)	$(19,108)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.